SCHEMBL1940209

SCHEMBL1940209

O=C(CO)NC(Sc1ncccc1C(=O)Nc1ccc(OC(F)(F)F)c(Cl)c1)c1ccncc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNLIP P16233 1/20 0.43
MALT1 Q9UDY8 1/20 0.42
KDR P35968 4/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 4/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
KMT2A Q03164 2/20 0.39
CSF1R P07333 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
TRPV1 Q8NER1 2/20 0.37
S1PR2 O95136 3/20 0.37
GRM4 Q14833 1/20 0.37
ABL1 P00519 1/20 0.37
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1942408 0.90 KDR (0.42) PNLIPMALT1KDRLMNAMAPT
SCHEMBL1940215 0.87 KDR (0.54) KDRMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1941872 0.83 KDR (0.52) KDRSMN1; SMN2KMT2ATRPV1
SCHEMBL1940229 0.83 KDR (0.59) KDRLMNANPC1SMN1; SMN2KMT2A
SCHEMBL1941558 0.82 RXFP1 (0.50) KDRLMNAMAPTKMT2ACSF1R
SCHEMBL1941697 0.82 KDR (0.52) KDRMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3926494 0.81 KDR (0.54) KDRMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL4018049 0.80 KDR (0.66) PNLIPMALT1KDRLMNAMAPT
SCHEMBL1941536 0.80 KMT2A (0.46) KDRLMNANPC1KMT2A
SCHEMBL1942109 0.79 KDR (0.54) KDRMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1717229-B1 NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN SANTEN PHARMACEUTICAL CO LTD (JP) 2011-06-15 EP claimed
US-7544703-B2 Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 US claimed
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US claimed
US-7544703-B2 Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 US disclosed
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein FLT4, FLT1, TIE1 PNLIP 4798/4885MALT1 2942/4885KDR 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.